584 related articles for article (PubMed ID: 32460120)
1. Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis.
Alasad YW; Asha MZ
Clin Neurol Neurosurg; 2020 Aug; 195():105900. PubMed ID: 32460120
[TBL] [Abstract][Full Text] [Related]
2. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
3. Network meta-analysis on efficacy and safety of different anti-CGRP monoclonal antibody regimens for prophylaxis and treatment of episodic migraine.
Shi M; Guo J; Li Z; Sun H; Yang X; Yang D; Zhao H
Neurol Res; 2021 Nov; 43(11):932-949. PubMed ID: 34281473
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials.
Yang CP; Zeng BY; Chang CM; Shih PH; Yang CC; Tseng PT; Wang SJ
Neurotherapeutics; 2021 Oct; 18(4):2639-2650. PubMed ID: 34580838
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
[TBL] [Abstract][Full Text] [Related]
7. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis.
Deng H; Li GG; Nie H; Feng YY; Guo GY; Guo WL; Tang ZP
BMC Neurol; 2020 Feb; 20(1):57. PubMed ID: 32061264
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis.
Soni P; Chawla E
Clin Neurol Neurosurg; 2021 Oct; 209():106893. PubMed ID: 34464833
[TBL] [Abstract][Full Text] [Related]
11. Migraine therapeutics differentially modulate the CGRP pathway.
Bhakta M; Vuong T; Taura T; Wilson DS; Stratton JR; Mackenzie KD
Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis.
Sun W; Cheng H; Xia B; Liu X; Li Y; Wang X; Liu C
Clin J Pain; 2023 Oct; 39(10):560-569. PubMed ID: 37278480
[TBL] [Abstract][Full Text] [Related]
13. Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety.
Lattanzi S; Brigo F; Trinka E; Vernieri F; Corradetti T; Dobran M; Silvestrini M
Drugs; 2019 Mar; 79(4):417-431. PubMed ID: 30793254
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin-gene-related peptide pathway mAbs and migraine prevention.
Paemeleire K; MaassenVanDenBrink A
Curr Opin Neurol; 2018 Jun; 31(3):274-280. PubMed ID: 29432219
[TBL] [Abstract][Full Text] [Related]
15. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
Nagaraj K; Vandenbussche N; Goadsby PJ
Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
[TBL] [Abstract][Full Text] [Related]
16. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis.
Wang X; Wen D; He Q; You C; Ma L
J Headache Pain; 2022 Sep; 23(1):105. PubMed ID: 36071388
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies for the prevention of migraine.
Raffaelli B; Neeb L; Reuter U
Expert Opin Biol Ther; 2019 Dec; 19(12):1307-1317. PubMed ID: 31550937
[No Abstract] [Full Text] [Related]
19. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial.
Dodick DW; Silberstein SD; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
JAMA; 2018 May; 319(19):1999-2008. PubMed ID: 29800211
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
Hong P; Wu X; Liu Y
Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]